For many patients with serious mitral valve regurgitation, surgery to repair or replace the defective valve are two options that each have a proven history of positive outcomes. But what about patients who have severe mitral regurgitation, but are at a high risk for surgery? The technology to help these patients appears close at hand. Results of the EVEREST II trial were published in the Jan. 10 issue of the Journal of the American College of Cardiology, and the research shows that the percutaneous MitraClip (Abbott) device reduced mitral regurgitation and improved clinical symptoms in a group of high surgical-risk patients.
To continue reading this article or issue you must be a paid subscriber.
Sign in
